MedTrace Logo

An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject

NCT01051414 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2015-10-09

No results posted yet for this study

Summary

To assess the efficacy and safety profile of co-administration of BMS-790052 and BMS-650032 for 24 weeks treatment.

Conditions

  • Hepatitis C Infection

Interventions

DRUG

BMS-790052

Tablets, Oral, 60 mg, daily, 24 weeks

DRUG

BMS-650032

Tablets, Oral, 1200 mg, daily, 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-09-30
Completion
2012-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01051414 on ClinicalTrials.gov